Intra-Cellular Therapies, Inc.
ITCI · NASDAQ
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Market Cap | $8,613,503 | $7,739,073 | $7,052,127 | $6,613,675 |
| - Cash | $306,948 | $464,312 | $695,056 | $141,569 |
| + Debt | $16,981 | $17,709 | $18,288 | $16,376 |
| Enterprise Value | $8,323,536 | $7,292,470 | $6,375,359 | $6,488,482 |
| Revenue | $199,223 | $175,159 | $161,388 | $144,866 |
| % Growth | 13.7% | 8.5% | 11.4% | – |
| Gross Profit | $178,818 | $159,855 | $150,034 | $134,966 |
| % Margin | 89.8% | 91.3% | 93% | 93.2% |
| EBITDA | -$29,088 | -$38,711 | -$27,594 | -$20,820 |
| % Margin | -14.6% | -22.1% | -17.1% | -14.4% |
| Net Income | -$16,885 | -$26,324 | -$16,220 | -$15,247 |
| % Margin | -8.5% | -15% | -10.1% | -10.5% |
| EPS Diluted | 0.56 | -0.25 | -0.16 | -0.16 |
| % Growth | 324% | -56.3% | 0% | – |
| Operating Cash Flow | -$13,078 | -$26,525 | $542 | -$34,116 |
| Capital Expenditures | $427 | -$696 | -$53 | $0 |
| Free Cash Flow | -$12,651 | -$27,221 | $489 | -$34,116 |